Supplemental announcement in relation to the 2025 annual report and the 2026 interim report
Filed with HKEX · Stock code 2142 · · 1 page · English
和鉑醫藥控股有限公司 HBM Holdings Limited (incorporated in the Cayman Islands with limited liability) (Stock Code: 02142) SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT AND THE 2026 INTERIM REPORT Reference is made to the annual report of HBM Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) for the year ended 31 December 2025 published on 28 April 2026 (the “202
Earlier from HBM
- Voluntary announcement - nona biosciences develops the world's first language model trained on fully human heavy-chain-only antibodies
- Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
- Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
- Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Later from HBM
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
- Inside information announcement - nmpa approval of batoclimab injection (subcutaneous injection) for the treatment of generalized myasthenia gravis
Follow HBM into a list and get an email when it puts out news.
Follow HBM